Physiological changes from ageing regarding pain perception and its impact on pain management for older adultsCME: Geriatric medicine Published on 2022-07-012024-09-04 Journal: Clinical medicine (London, England) [Category] 대상포진, [키워드] Ageing neuropathic nociceptive Pain Pharmacodynamics [DOI] 10.7861/clinmed.22.4.phys PMC 바로가기 [Article Type] CME: Geriatric medicine
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus ErythematosusPharmacometrics Published on 2022-05-212024-09-04 Journal: Journal of clinical pharmacology [Category] 대상포진, [키워드] anifrolumab interferon Pharmacodynamics pharmacokinetics systemic lupus erythematosus (SLE) [DOI] 10.1002/jcph.2054 PMC 바로가기 [Article Type] Pharmacometrics
Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus ErythematosusPharmacometrics Published on 2022-05-212024-09-04 Journal: Journal of clinical pharmacology [Category] 대상포진, [키워드] Drug development modeling and simulation Pharmacodynamics Population pharmacokinetics rheumatology [DOI] 10.1002/jcph.2055 PMC 바로가기 [Article Type] Pharmacometrics
Evidence-based dosing of convalescent plasma for COVID-19 in future trials향후 시험에서 COVID-19에 대한 회복기 혈장의 증거 기반 투여Review Published on 2022-05-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 animal model antibody Antibody test CLOCK convalescent plasma ConvP coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 criteria Donor Donor selection donors dose doses Dosing Efficacy Evidence Guidance identifying Immunity International international units monoclonal monoclonal antibodies monoclonal antibody mRNA vaccination neutralize neutralizing antibody neutralizing antibody titres neutralizing monoclonal antibodies omicron Omicron variant pandemic Patient care performed Pharmacodynamics pharmacokinetics plasma unit premise respiratory SARS-CoV-2 selection process Support the patient therapy titre Treatment Trial turn variant variants Virus neutralization virus-neutralizing virus-neutralizing antibody Volume [DOI] 10.1016/j.cmi.2022.01.026 PMC 바로가기 [Article Type] Review
PharmGKB summary: Acyclovir/Ganciclovir PathwayArticle Published on 2022-04-292024-09-04 Journal: Pharmacogenetics and genomics [Category] 대상포진, [키워드] acyclovir Ganciclovir NUDT15 Pharmacodynamics pharmacogenomics pharmacokinetics [DOI] 10.1097/FPC.0000000000000474 PMC 바로가기 [Article Type] Article
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)Research article Published on 2022-04-012022-10-05 Journal: Thérapie [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome Adverse drug reaction Antiviral association clinician Combination complex Contact coronavirus Course cysteine protease draft drug drug monitoring drug-drug interaction Efficacy enhancer enzyme Final French guideline help high risk management Modification modifications MPro National Nirmatrelvir objective Participants patients treated Paxlovid Pfizer Pharmacodynamics pharmacokinetic pharmacokinetics Pharmacology Pragmatic Prevent primary care protease recommendation recommendations Result Ritonavir SARS-CoV-2 secure Society therapeutic therapeutic strategy Therapeutics Treatment [DOI] 10.1016/j.therap.2022.03.005 [Article Type] Research article
Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A ReviewMicrobiology Published on 2022-02-152022-10-31 Journal: Frontiers in Microbiology [Category] COVID-19, [키워드] Anti-inflammatory Autoimmune diseases bloodstream Characteristics China Clinical outcome combating coronavirus disease Corticosteroid Corticosteroids COVID-19 COVID-19 patient COVID-19 patients database Dexamethasone Direct disease dosage drug drugs genomic effects immune response immune system Immunocompromised immunomodulatory Impact Inflammation Inflammatory inflammatory impacts inhibit Interaction leukemia literature management medication Methylprednisolone modulate Multiple myeloma non-genomic non-Hodgkin’s lymphoma Open-label pandemic disease Patient Perspective Pharmacodynamics pharmacokinetics physical Pneumonia Population produced Randomized recommendation RECOVERY trial reduce Research review role Safe Science searched seeking shown supplemental oxygen survival Symptom tissue toxicology Trial use of corticosteroid Vaccine WHO with COVID-19 [DOI] 10.3389/fmicb.2022.813358 PMC 바로가기 [Article Type] Microbiology
Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and PharmacodynamicsCOVID 폐렴에서 정맥내 나파모스타트 메실레이트의 무작위 대조 시험: 안전성, 약동학 및 약력학을 조사하기 위한 1b/2a상 실험 연구Clinical Trial Published on 2022-02-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 신약개발, 임상, 치료제, [키워드] 95% CI Administered adverse events Analysis Anti-inflammatory Anticoagulant anticoagulant effect anticoagulant effects antiviral activity assigned average characterisation Controlled trial COVID COVID-19 COVID19 creatinine credible interval demonstrated dose Edinburgh Endpoint endpoints Evidence evidence of Hospital stay hospitalised hospitalised patient Hospitalised patients inactive independent Infectious diseases intravenous intravenous infusion manuscript maximum mean difference mesylate metabolites nafamostat Nafamostat mesylate observé Odds ratio open open label Oxford oxygen Patient patients Pharmacodynamics pharmacokinetics phase Phase 2 PK data plasma platform Pneumonitis Primary outcome Primary outcomes progressed randomised randomised controlled trial Randomly rate ratio receive reported Repurposed drug Research respiratory Respiratory medicine response SARS-CoV-2/COVID-19 Seven significantly higher significantly more SOC Standard of care statistically significant difference therapy Tolerability Total Total manuscript word count. Trial university with COVID-19 [DOI] 10.1016/j.ebiom.2022.103856 PMC 바로가기 [Article Type] Clinical Trial
Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and in silico COVID-19 drug candidate moleculesResearch article Published on 2022-01-012022-10-05 Journal: Saudi Journal of Biological Sciences [Category] 신약개발, 치료제, [키워드] analyzed approach Arbidol bind binding binding energy binding free energy binding site blood plasma calculated Carmofur complexes Compound compounds coronavirus disease COVID-19 daclatasvir demonstrated dihydroergotamine disulfiram drug drug candidate Effects evaluate geometric HAS Human Human serum albumin Hydrogen bond hydrophobic interactions identify in silico inhibitor interacting residue mechanism MM/PBSA moderate molecular molecular docking Molecular dynamics simulation molecular interaction Molecular mechanics P-glycoprotein P450 paritaprevir permeation Pharmacodynamics pharmacokinetic pharmacokinetics pharmacological prevalent Protein saquinavir selected serum albumin Serum protein stability therapeutic therapeutic molecules were used [DOI] 10.1016/j.sjbs.2021.09.042 [Article Type] Research article
Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection경증에서 중등도의 COVID-19 감염 환자에서 중화 항체 Bamlanivimab 및 Etesevimab의 인구 약동학 및 약력학Clinical Trial Published on 2021-11-012022-09-11 Journal: Clinical Pharmacology and Therapeutics [Category] MERS, 임상, 진단, 치료제, [키워드] 95% confidence interval Administered age bamlanivimab baseline clinical trial clinical trials coronavirus disease Coronavirus disease 2019 COVID-19 dose doses drug Drug administration drug concentration Emergency use authorization etesevimab greater hepatic impairment indicated Mild moderate disease Neutralizing antibodies neutralizing antibody Observed onset of symptoms optimal dose Patient Pharmacodynamics pharmacokinetics Placebo Population receiving reduction in reductions in relative serum Sex Simulation the antibodies Treatment Viral Viral load was used [DOI] 10.1002/cpt.2420 PMC 바로가기 [Article Type] Clinical Trial